Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Mesoblast
- 12 Oct 2016 Planned End Date changed from 1 Jan 2017 to 1 Sep 2017.
- 12 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
- 25 Aug 2016 According to a Mesoblast Limited media release, the company plans to conduct a futility analysis in Q4 of 2016.